Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363168 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
A Phase 1 study of Choroidal Neovascularization, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT00363168 is a Phase 1 study of Choroidal Neovascularization that has completed, run by Johns Hopkins University. The registered enrollment target is 7 participants, below the 185-participant average among 7 other Choroidal Neovascularization trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00363168, a Phase 1 study of Choroidal Neovascularization, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to look at the effects of an experimental drug, ranibizumab, on a condition called "predominantly hemorrhagic subfoveal choroidal neovascularization (CNV)" due to wet age-related macular degeneration. A predominantly hemorrhagic CNV lesion is diagnosed when at least 50% of the choroidal neovascular lesion is occupied by blood under the retina. We want to find out if injections of ranibizumab into the eye will help patients with this condition.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
Maryland
- The Wilmer Eye Institute at Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363168
The ClinicalTrials.gov registry entry for NCT00363168 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 7 other Choroidal Neovascularization trials with a reported enrollment target (96% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Choroidal Neovascularization appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00363168 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00363168 about?
NCT00363168 is a clinical study titled "Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial". This research is being done to look at the effects of an experimental drug, ranibizumab, on a condition called "predominantly hemorrhagic subfoveal choroidal neovascularization (CNV)" due to wet age-related macular degeneration. A predominantly hemorrhagic CNV lesion is diagnosed when at least 50% ...
What is the current status of trial NCT00363168?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2006-08. Estimated completion is 2009-05.
What conditions does trial NCT00363168 study?
This clinical trial studies the following conditions: Choroidal Neovascularization.
What interventions are being tested in trial NCT00363168?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00363168?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00363168 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroidal Neovascularization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
COMPLETED · NA
-
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
COMPLETED · Phase 2
-
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.